Where can I buy Quizatinib in the country?

Quizartinib (Quizartinib) is a new type of FLT3 tyrosine kinase inhibitor, mainly used to treat acute myeloid leukemia (AML) associated with FLT3-ITD mutation. Its targeted mechanism of action is clear and is regarded as an important breakthrough in the field of precision therapy. In 2023, the U.S. FDA has approved quizartinib as a combination treatment for patients with newly diagnosed FLT3-ITD-positive AML, marking a further improvement of the drug's clinical status in the international leukemia treatment system. However, in the Chinese mainland market, the listing process of quizartinib is still in the advancement stage. According to public information, as of January 2025, the drug is being applied for marketing in China and has not yet received formal approval from the National Medical Products Administration (NMPA).

Therefore, currently in mainland China, Quizartinib has not yet achieved local registration and marketing of the original drug. In other words, patients are temporarily unable to purchase the drug directly in domestic general hospital pharmacies or the medical insurance system. However, with the gradual improvement of the drug regulatory system and the development of cross-border medical channels, patients can still obtain drug treatment through certain compliance methods.

A common way is to introduce overseas original drugs through overseas medical service platforms, third-party imported drug service agencies or certified cross-border medical institutions. These institutions usually establish cooperative relationships with regular overseas pharmacies or pharmaceutical companies and can help patients apply for temporary import of international drugs or complete the cross-border process of individualized medication through a doctor's prescription.

The currently available overseas versions of Quizartinib are mainly from Europe, the United States and other countries, and the common trade name isVanflyta. Overseas selling prices vary slightly due to different regions and specifications. Usually the cost of a course of treatment is relatively high, and patients need to make a decision based on their own financial situation and condition. It is worth noting that since this drug has not yet been approved for marketing in mainland China, you must be wary of non-compliant gray channels when selecting drug sources to prevent the purchase of counterfeit drugs or unverified generic drugs.

Reference materials:https://go.drugbank.com/drugs/DB12874